Navigation Links
New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V)
Date:12/7/2009

l program for Vimpat® has yielded safety and efficacy data totaling almost 3,000 patient years of exposure," said Dr. Jacqueline French, Director of the Clinical Trials Consortium at the Comprehensive Epilepsy Center at New York University Langone Medical Center.

Vimpat® was launched in the U.S. in May 2009 as an add-on therapy for the treatment of partial-onset seizures in people with epilepsy who are 17 years and older, and is available as oral tablets and as an intravenous (IV) infusion to allow for consistent treatment in a hospital setting. In Europe, Vimpat® (film-coated tablets, syrup, and solution for infusion) is approved as adjunctive therapy for the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy, aged 16 years and older. Vimpat® has a novel mechanism of action that is different from all currently available AEDs, although the precise mechanism by which Vimpat® exerts its antiepileptic effect in humans is not yet clear.

Summary of Vimpat® Data Presented at 2009 AES Annual Meeting

Abstract: Long-term Efficacy of Lacosamide for Partial-Onset Seizures: An Interim Evaluation of Completer Cohorts Exposed to Lacosamide for up to 36 Months

This analysis of phase II/III open-label extension trials demonstrated that lacosamide produced long-term, sustained efficacy in patients with partial-onset seizures who completed 6, 12, 18, 24, 30, or 36 months of treatment. Researchers noted that given the study's "nested cohort" design, with each cohort including patients remaining from the shorter-duration cohort, the expected attrition of non-responders is accounted for, and efficacy findings reflect real-world use.

  • The reduction in seizure frequency associated with lacosamide was sustained across all duration cohorts, as was the proportion of responders - patient
    '/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings
2. MathMagic Personal 4.8 for Windows Now Supports Google Docs and Zoho Equation
3. The Chopra Center for Wellbeing Launches Vedamune: An Ayurvedic Supplement to Support The Immune System
4. Thomson Reuters Survey: Most Americans Support Public Option in Healthcare Reform Legislation but Are Skeptical Healthcare Will Improve in 2010
5. FamilyLife Supports Military Marriages in Atlanta
6. eCube Delivers Linux on System z Support for NXTera High Performance Middleware
7. New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option
8. Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog
9. MISSION Skincare(R) Supports GNCs Efforts To Raise Money for St. Jude Childrens Research Hospital(R)
10. NACDS Supports FDA Enforcement Against Rogue Internet Pharmacy Websites
11. Computerized order entry/decision support systems: Effective solution to managing imaging utilization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Dennis Thompson HealthDay Reporter ... combination of therapy and antidepressants appears to best help ... reports. Four out of five people suffering from ... recovery when treated with cognitive therapy plus antidepressant medication, ... didn,t work much better than drugs alone in helping ...
(Date:8/21/2014)... 2014 Seattle, WA chiropractors Dr. ... Eastlake Chiropractic and Massage Center have recently welcomed ... Rina Lang, LMP and Mike Larios, LMP have ... massage techniques, and have developed their expertise working in ... particularly important in a clinical environment where massage is ...
(Date:8/21/2014)... August 21, 2014 The results of ... in The Journal of the American Medical Association (JAMA) ... cancers and reduces unnecessary recalls. Memorial Healthcare System was ... study. , “This study confirms what we already know ... cancers we want to find and, at the same ...
(Date:8/21/2014)... The second bellwether trial involving ... has begun in Massachusetts state court. The device ... Law Group LLP, a national personal injury law ... stemming from the implantation of mesh products, provides ... injuries suffered at http://www.wehelpwomen.com/transvaginal-mesh/ . , Maria ...
(Date:8/21/2014)... The Swedish-American Life Science Summit, (SALSS) ... on the Future of Medicine and the challenges ... , With the mission to turn new sciences ... business and science. "Over the years SALSS has ... diverse community with representatives challenging the boundaries of ...
Breaking Medicine News(10 mins):Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 2Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 3Health News:Dr. Mary Hayes: Study Shows 3D Mammography Finds More Invasive Cancers While Reducing Unnecessary Recalls 2Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2
... , , , ... DST Health Solutions, a leading provider of software and services ... certification, a designation demonstrating its commitment to quality product development. ... Registrar, an independent auditing firm, for meeting the guidelines set ...
... LEBANON, Tenn., July 28 Health Connect Partners, Inc. ( ... the title sponsor of its 2009 Fall Hospital Pharmacy Conference. ... up to 200 directors of pharmacy from some of the largest ... sessions led by healthcare industry experts, the Hospital Pharmacy Conference will ...
... COLORADO SPRINGS, Colo., July 28 Now that summer is in ... across the county. , , With millions enjoying their ... for home pool and hot tub safety is urgent. , , ... home pool and hot tub owners to make safety their priority by following ...
... , WILTON, Conn., July 28, ... Friday, July 24 and Saturday, July 25 in Chicago, Eucerin was ... incidental sun exposure and give them a glimpse into their skin,s ... year marked Eucerin,s first appearance at the annual BlogHer Conference, connecting ...
... , CHICAGO, July 28 When at the pool ... the harmful rays of the sun. But do we remember to apply sunscreen to ... on the feet from unprotected sun exposure, and overlook applying sunscreen to the area. ... of the foot is prevalent and can even be fatal if not caught early. ...
... Mylan Inc. (Nasdaq: MYL ) today reported that in ... proactively and as a courtesy had contacted the U.S. Food and ... a recent news article. As a result, the FDA visited the ... the baseless accusations in the article were unfounded. The FDA noted ...
Cached Medicine News:Health News:DST Health Solutions Achieves ISO 9001:2008 Certification 2Health News:Cardinal Health Announced as Title Sponsor of the Health Connect Partners' 2009 Fall Hospital Pharmacy Conference 2Health News:Seven Tips for Safer Home Swimming Pools and Hot Tubs 2Health News:Eucerin Provides BlogHer Attendees With a Glimpse Into Their Skin's Future With Proprietary 'Time Machine' Aging Simulator 2Health News:Sunscreen on Your Feet? Doctors Urge Sunscreen Use and Exams to Prevent Skin Cancer on Feet 2Health News:Mylan Reports That the FDA Determined That All Accusations Were Unfounded 2
(Date:8/21/2014)... SAN JOSE, Calif. , Aug. 21, 2014 /PRNewswire/ ... a medical device company that pioneered the use of ... surgical (MIS) device indicated for fusion of the sacroiliac ... ) published an update to its Lumbar Fusion ... MIS SI joint fusion procedure.  The policy states that ...
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium ... a specialty biopharmaceutical company, today announced positive results ... collagenase clostridium histolyticum (or CCH) for the treatment ... cellulite. In the Phase 2a trial, all three ... high (0.84mg)) showed an improvement in the appearance ...
(Date:8/20/2014)... , Aug. 20, 2014  The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Indiana blocked the sale of ...
Breaking Medicine Technology:SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... candidate, has been granted orphan drug designation from the ... of pediatric Clostridium difficile infection (CDI).  This ... covers all formulations of fidaxomicin used to treat ...
... 2011 ULURU Inc. (NYSE Amex: ULU), ... a portfolio of wound management and oral care products, today ... 5,000,000 shares of its common stock at a price per ... an institutional investor, resulting in gross proceeds of approximately $500,000. ...
Cached Medicine Technology:Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 2Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 3Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 4ULURU Inc. to Raise $500,000 in Registered Direct Offering 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: